DNABased Screening and Diagnostics for Prostate Cancer

1
DNA-Based Screening and Diagnostics for Prostate
Cancer

• Dr. Miroslava Cuperlovic-Culf
• AMF-BMRI
• Moncton, NB

Dr. Nabil Belacel IIT-NRC Moncton, NB
2
Biomarkers marker or indicators of a clinical
process or phenotype
Tumour burden
Risk assesment
Process
Monitoring for recurrence
Screening
Classification, stage, grade
Goal
3
The Market
Market Trends

• World Molecular Diagnostics Market 2105 US 35
  billion

• Early diagnosis
• Personalized Medicine
• Cost decrease
• Sensitivity and specificity increase

4
BMRI/NRCProstate Cancer Genetic Marker Panel

• Under 10 gene marker DNA Microarray determined
  panel
• Independent database validation
• In-house developed procedure and algorithm
• Accuracy in tissue sample analysis
• 98 specificity
• 96 sensitivity
• Platform technology for screening, diagnosis and
  treatment
• Applicable to other cancer types and genetic
  diseases

5
The Potential

• Short Term
• Improved diagnostic capability of tissue samples
• Some cost avoidance
• Increased accuracy certainty
• Medium Term
• Replace PSA
• Non-invasive diagnostics
• Significant cost avoidance

• Long Term
• Personalized medicine treatment programs
• Pre-onset early screening
• Translate capability to other cancers
• Improved method of classification of cancer types

6
Acknowledgements
ACOA Atlantic Innovation Fund Dr. Georges L.
Dumont Hospital Foundation Doolys NRC

• BMRI
• Dr. Rodney Ouellette
• NRC-IIT
• Georges Corriveau
• David McGuire